Burroughs Wellcome and the Pricing of AZ...
Liedtka, Jeanne M.
Burroughs Wellcome and the Pricing of AZT (A)
E-0074 | Published April 15, 1991 | 9 pages Case
Collection: Darden School of Business
Product Details
This case focuses on the development of AZT, the first drug approved for the treatment of AIDS, and the issues faced by its U.K. producer, Wellcome PLC, as it decides how to set the drug's price. The case includes brief overviews of the disease itself, drugs in development to treat it, the pharmaceutical industry and its practices, and the history of Wellcome PLC and its U.S. subsidiary, Burroughs Wellcome. The A case concludes with analysts' predictions for the soon-to-be-announced price of AZT. See also the B case (UVA-E-0075) and the C case (UVA-E-0076).
0
Get Ahead in Class
Clear, Complete, and Concise: Avoiding t...
Lipson, Marc L.
Business Valuation in Mergers and Acquis...
Schill, Michael J....
A Brief Introduction to Macroeconomics
Murphy, Daniel
Moral Theory, Frameworks, and the Langua...
Wicks, Andrew C.; ...
Three Empirical Methods for Calculating ...
Zhang, Zhihao; Whi...
The Basics of Multivariate Regressions i...
Batova, Tatiana
Advanced Tableau Tips and Tricks
Palomba, Anthony
Digital Marketing Metrics: Measuring Wha...
Venkatesan, Rajkum...
Disruption, Response, and Transformation...
Chen, Ming-Jer; Mc...
Using AI to Expand Your Leadership Commu...
Murray, Meghan
Understanding Organizational Culture: An...
Martin, Sean; Kemp...
A Brief Introduction to Managerial Accou...
Lynch, Luann J.
How to Prototype a Prototype
Chao, Raul O.
The Strategist’s Toolkit
Lenox, Michael; Ha...
Finance People
Schill, Michael J.